Epilepsy is a brain disorder having tendency of predisposition and to generate epileptic seizures by producing the neurobiologic, cognitive, psychological and social consequences. A seizure is a chronic disease affecting around 50 million of the population worldwide. In the beginning partial seizures are limited to some parts of cerebral cortex. Self-medication and patient compliance is important part for therapy of disorder like partial seizures. “Engulfment of medicine during seizures is very difficult for patient. In such case requirement of tablets which can disintegrate in mouth is required. Hence here lacosamide is considered as model drug for design of orally disintegrating tablets. Lacosamide is a BCS Class I drug with bitter taste. The oral bioavailability of marketed sample of lacosamide tablets is approximately 100%. The C max of Lacosamide is seen in the range 0.5 to 4 hours post-dose. The present studies are undertaken based on the hypothesis that taste masked oro-dispersible tablet will exclude the use of injectable and increase patient compliance. The bitter taste of Lacosamide can be masked with the help of Kollicot smart seal 30D with concentration of 10%w/w, Formulation LCMDB5 is selected for optimum formulation who fullfill all the criteria for ODT for lacosamide. Lacosamide is tested for DSC, IR and XRD and found acceptaable with required specification. The excipient used for manufacturing of ODT is found to deliver their best performance during manufacturing and testing of finished product. The developed technology for Lacosamide with taste masking improves patient compliance. The need for such medication for condition like partial onset seizures will be more helpful than conventional tablets and could prove to be a major breakthrough for patient oral administration.
Loading....